Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6016 AL 6030

Therapeutic compliance of nanomedicine in Alzheimer's disease

Wilson B.

Nanomedicine (Lond). 2011 Sep;6(7):1137-9. doi: 10.2217/nnm.11.114.

Antioxidant pathways in Alzheimer's disease: possibilities of intervention

Viña J, Lloret A, Giraldo E, Badia MC, Alonso MD.

Curr Pharm Des. 2011 Dec;17(35):3861-4. doi: 10.2174/138161211798357755.

A randomized controlled trial of an activity specific exercise program for individuals with Alzheimer disease in long-term care settings

Roach KE, Tappen RM, Kirk-Sanchez N, Williams CL, Loewenstein D.

J Geriatr Phys Ther. 2011 Apr-Jun;34(2):50-6. doi: 10.1519/JPT.0b013e31820aab9c.

Natural substances and Alzheimer's disease: from preclinical studies to evidence based medicine

Mancuso C, Siciliano R, Barone E, Preziosi P.

Biochim Biophys Acta. 2012 May;1822(5):616-24. doi: 10.1016/j.bbadis.2011.09.004. Epub 2011 Sep 14.

Use of memantine for the treatment of dementia

Lo D, Grossberg GT.

Expert Rev Neurother. 2011 Oct;11(10):1359-70. doi: 10.1586/ern.11.132.

Opportunities and challenges in developing Alzheimer disease therapeutics

Iqbal K, Grundke-Iqbal I.

Acta Neuropathol. 2011 Nov;122(5):543-9. doi: 10.1007/s00401-011-0878-z. Epub 2011 Sep 30.

A review of the effects of memantine on clinical progression in Alzheimer's disease

Wilkinson D.

Int J Geriatr Psychiatry. 2012 Aug;27(8):769-76. doi: 10.1002/gps.2788. Epub 2011 Oct 1.

Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: secondary analyses from a randomized, controlled trial

Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P.

J Nutr Health Aging. 2011 Aug;15(8):672-6. doi: 10.1007/s12603-011-0339-3.

A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Int Rev Neurobiol. 2011;100:191-215. doi: 10.1016/B978-0-12-386467-3.00010-8.

APP transgenic mice and their application to drug discovery

Howlett DR.

Histol Histopathol. 2011 Dec;26(12):1611-32. doi: 10.14670/HH-26.1611.

Clinical research on comprehensive treatment of senile vascular dementia

Chen LP, Wang FW, Zuo F, Jia JJ, Jiao WG.

J Tradit Chin Med. 2011 Sep;31(3):178-81. doi: 10.1016/s0254-6272(11)60036-8.

Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease

Williams RJ, Spencer JP.

Free Radic Biol Med. 2012 Jan 1;52(1):35-45. doi: 10.1016/j.freeradbiomed.2011.09.010. Epub 2011 Sep 17.

Current and emerging drug treatment options for Alzheimer's disease: a systematic review

Herrmann N, Chau SA, Kircanski I, Lanctôt KL.

Drugs. 2011 Oct 22;71(15):2031-65. doi: 10.2165/11595870-000000000-00000.

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L.

Arch Neurol. 2012 Feb;69(2):198-207. doi: 10.1001/archneurol.2011.1538. Epub 2011 Oct 10.

Two galantamine titration regimens in patients switched from donepezil

Engedal K, Davis B, Richarz U, Han J, Schäuble B, Andreasen N.

Acta Neurol Scand. 2012 Jul;126(1):37-44. doi: 10.1111/j.1600-0404.2011.01594.x. Epub 2011 Oct 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias